出血翻修对左心室辅助装置植入后结局的影响
该回顾性研究分析了2006年1月至2016年12月在维也纳医科大学心脏外科接受连续流左心室辅助装置(LVAD)植入的257例成人患者,发现14%的患者因出血接受手术翻修,出血翻修与LVAD支持期间生存率显著降低相关(总体p=0.007),且并发症率更高。
要点
- 出血翻修与LVAD支持期间生存率显著降低独立相关。
- 出血翻修组 prolonged ventilation、ICU停留、住院、肾脏替代治疗和卒中率更高。
- 临时右心室辅助装置同期植入和年龄是出血翻修的独立危险因素。
核心结论
- 出血翻修与LVAD支持期间生存率显著降低和发病率显著增加相关。
- 术前、术中和术后预防策略可能有助于预防这一危及生命的并发症。
研究设计与样本
- 回顾性分析2006年1月至2016年12月单中心257例连续流LVAD成人受体。
- LVAD类型包括HeartWare HVAD、HeartMate II和HeartMate 3。
- 主要结局为LVAD支持期间生存率,次要结局包括延长通气、ICU停留、住院、肾脏替代治疗和卒中率。
主要发现
- 多变量Cox比例风险模型显示出血翻修与LVAD支持期间生存率降低显著相关(3个月HR 2.04,95%CI 1.20-3.48;6个月HR 1.63,95%CI 0.95-2.82;12个月HR 1.30,95%CI 0.69-2.46;24个月HR 1.04,95%CI 0.48-2.26;总体p=0.007)。
- 出血翻修组次要结局发生率显著高于无出血翻修存活出院患者。
- 临时右心室辅助装置同期植入(p=0.002)和年龄(p=0.028)是出血翻修的独立危险因素。
临床怎么用
- LVAD植入患者应重视出血翻修风险,尤其是高龄和同期植入临时右心室辅助装置者。
- 采取术前、术中和术后预防策略可能降低出血翻修及相关不良结局风险。
局限性
- 回顾性单中心研究,样本量有限,结论需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few reports have described associations between a bleeding revision and outcomes after implantation of a continuous-flow left ventricular assist device (LVAD). METHODS: We retrospectively analyzed all adult recipients of a continuous-flow LVAD who were operated on between January 2006 and December 2016 at the Division of Cardiac Surgery, Medical University of Vienna (N = 257). LVAD types were HeartWare HVAD (Medtronic, Minneapolis, MN), HeartMate II (Abbott [Thoratec], Abbott Park, IL), and HeartMate 3 (Abbott [Thoratec]). The primary outcome variable was survival during LVAD support. Secondary outcome variables were rates of prolonged ventilation, intensive care unit stay, hospital stay, renal replacement therapy, and stroke. We additionally investigated risk factors for a bleeding revision. RESULTS: Thirty-six patients (14%) underwent surgical revision for bleeding. In a multivariable Cox proportional hazards model, bleeding revision was associated with significantly reduced survival during LVAD support (3 months: hazard ratio [HR], 2.04; 95% confidence interval [CI], 1.20 to 3.48; 6 months: HR, 1.63; 95% CI, 0.95 to 2.82; 12 months: HR, 1.30; 95% CI, 0.69 to 2.46; 24 months: HR, 1.04; 95% CI 0.48 to 2.26; overall p = 0.007). Rates of secondary outcome variables were substantially higher in the revision group compared with patients who survived the hospital stay without a bleeding revision. Concomitant implantation of a temporary right ventricular assist device (p = 0.002) and age (p = 0.028) were independent risk factors for a bleeding revision. CONCLUSIONS: A bleeding revision is associated with significantly reduced survival and substantially increased morbidity during LVAD support. Preoperative, intraoperative, and postoperative prophylactic strategies may help to prevent this life-threatening complication.
引用
- Angleitner P, Simon P, Kaider A, et al. Impact of Bleeding Revision on Outcomes After Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2019. PMID: 30851258. doi:10.1016/j.athoracsur.2019.01.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。